Zogenix Completes Management Team with Cynthia Robinson, Ph.D., CDO, & Mark Thompson, VP, Sales & Managed Markets
SAN DIEGO, Calif. - (April 17, 2008): Zogenix, Inc. (”Zogenix”), a private, specialty pharmaceutical company, today announced that Cynthia “Candy” Robinson has joined the company as Chief Development Officer (CDO), and Mark Thompson has joined as Vice President, Sales and Managed Markets.
Before joining Zogenix, Dr. Robinson had served as a consultant to the company. She also served as Senior Vice President, Development Operations at InterMune, from 2004 to 2007. Prior to InterMune, Inc., Dr. Robinson spent fifteen years at Elan Pharmaceuticals, Inc., where, in her culminating position as Vice President, Project Management, she oversaw a portfolio of 14 global development programs from pre-clinical through commercialization, including multiple products in the therapeutic areas of CNS and pain. These efforts resulted in nine U.S. New Drug Applications (NDAs), four European Marketing Authorization Applications (MAAs), and four U.S. product launches. Dr. Robinson holds a B.S. in Chemistry and a Ph.D. in Organic Chemistry from the University of Alabama.
Mr. Thompson brings nearly 30 years of pharmaceutical sales and senior management experience to Zogenix. He previously served as Vice President, Sales at Valeant Pharmaceuticals, Inc., where he led both the hepatology and neuroscience sales teams, as well as the management of sales operations, analytics and training. Prior to Valeant, Mr. Thompson was the Vice President, Sales, at InterMune for two years, and Vice President, Sales, at SkinMedica for two years. He also served as Senior Director, National Sales for Elan Biopharmaceuticals, Inc., Primary Care Division, leading a sales team of approximately 500. Mr. Thompson began his pharmaceutical career at Glaxo, Inc., and over a 21-year career there rose to the level of Regional Vice President, where his responsibilities included sales of Imitrex® and other CNS products.
“Both Candy and Mark are welcome additions to complete our management team,” said Roger Hawley, Chief Executive Officer of Zogenix. “Candy will immediately focus on driving our clinical development activities for ZX002, which we expect to enter Phase 3 clinical trials in the second half of this year. Mark will play a key role as we build our sales and managed markets organization in preparation for a potential launch of sumatriptan DosePro™ in early 2009, subject to the receipt of FDA approval. We believe their expertise in CNS products, migraine and pain, from both the clinical and commercial perspectives, will further strengthen our strategic and implementation capabilities.”
Zogenix, Inc., with offices in Emeryville and San Diego, CA, is a private, specialty pharmaceutical company with two proprietary product candidates in late-stage development for the treatment of central nervous system(CNS) disorders and pain. The company’s lead product candidate, sumatriptan DosePro™ (previously Intraject®), enables needle-free subcutaneous delivery of sumatriptan for the treatment of acute migraine and cluster headache. Zogenix submitted a New Drug Application with the U.S. Food and Drug Administration for sumatriptan DosePro in December 2007, and it was accepted for filing by the FDA in March 2008. Zogenix’s second product candidate, ZX002, is a novel, controlled release formulation of hydrocodone for the treatment of chronic pain. This product candidate has completed Phase 2 clinical trials, and the company anticipates initiating the Phase 3 clinical program in the second half of 2008. The company also plans to license the patented DosePro drug-delivery system to other companies. For additional information, visit www.zogenix.com.
Zogenix, DosePro™ and INTRAJECT® are trademarks of Zogenix, Inc.
Imitrex™ is a registered trademark of GlaxoSmithKline.
Chief Financial Officer